表皮生长因子受体靶向重组T7噬菌体抗肿瘤疫苗的免疫活性

Immune activity of the anti-cancer vaccine of recombinant bacteriophage T7 targeting epidermal growth factor receptor

目的探讨表皮因子受体为靶向,重组T7噬菌体疫苗在体诱导的免疫活性。方法用构建的重组T7噬菌体疫苗免疫动物,Dot-Blot和流式细胞仪检测产生的特异性抗体,MTT法检测产生的特异性杀伤肿瘤细胞活性。结果实验组动物均产生特异性抗体,与A431细胞结合的阳性细胞率分别为37.6%、47.6%和35.1%;T7415-1b-90和T7415-1b-132实验组均诱导产生对A431细胞的特异性杀伤作用,检测的ODE+T与对照组相比具有显著性差异(P<0.01);T710-3b-638实验组对肿瘤细胞无杀伤作用。结论异源EGFR分子构建的重组T7噬菌体疫苗可以诱导机体产生体液免疫反应和细胞免疫反应。

Objective To probe the immune activity of recombinant bacteriophage T7 inducing in vivi targeting epidermal growth factor receptor(EGFR).Methods Specific antibody was detected with Dot-Blot and Flow Cytometry,and specific cytotoxic responses were detected with MTT method,which were raised targeting EGFR after injection of constructed vaccine.Results In the experimental groups,the specific antibodys were detected,and the positive rate of A431 combined with immunization mice serum were 37.6%,47.6% and 35.1%,respectively.The specific cytotoxic response was induced targeting A431 cells in experimental groups of T7415-1b-90 and T7415-1b-132 bacteriophage,and the OD_(E+T) had statistically significant difference compared with control groups (P<0.01).There was not specific cytotoxic response in the experimental group of T710-3b-638 bacteriphage.Conclusion The recombinant bacteriophage T7 vaccine constructed with xenogeneic homologous molecules may induce humoral immune responses and cellular immune responses.